Saturday, December 27, 2025 | 09:10 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Lupin hits new high

Since February 23, the stock rallied 15% compared with 1% decline in CNX Nifty and 9% rise in CNX Pharma index.

SI Reporter Mumbai
Shares of Lupin were trading higher by 2% at Rs 1,901, after hitting a record high of Rs 1,917 on the National Stock Exchange (NSE) in otherwise weak market.

Since February 23, the stock rallied 15% from Rs 1,648 after the company said it has received the final approval for its product, a generic version of Allergan Inc's Lumigan Ophthalmic Solution, from the US Food and Drug Administration (USFDA). The CNX Nifty declined 1%, while CNX Pharma index gained 9% during the same period.

Thus far in 2015, shares of pharmaceutical company zoomed 34% against less than 5% rise in the benchmark index.

Analyst at Kotak Securities recommends a ‘buy’ rating on the stock with target price of Rs 2,055.

“Lupin is awaiting approval for Nexium generic from USFDA and had indicated launching it in 4QFY15. Nexium is a US$2.7 billion opportunity in the US with only one generic player - Teva. We believe FDA approval of Nexium generic will be a key driver in the near-term for US sales and can add US$100 million or around 10% to LPC's US revenues,” Meeta Shetty analyst at Kotak Securities in report dated March 9, 2015.
 
 

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 10 2015 | 2:55 PM IST

Explore News